Institut De Recherches Internationales Servier
Clinical trials sponsored by Institut De Recherches Internationales Servier, explained in plain language.
-
Esophageal cancer drug combo trial pulled before starting
Disease control TerminatedThis study was designed to test a new drug (S095033) combined with a standard chemotherapy (paclitaxel) in people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to see if the combination was safe and could shrink tumors. However, the trial was withdr…
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 29, 2026 02:22 UTC
-
New drug combo shows promise in early cancer trial, but expansion halted
Disease control OngoingThis early-phase study tested a new drug (S095029) alone and with another drug (Sym021) in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The planned expansion to test…
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 29, 2026 02:22 UTC
-
New drug combo targets hard-to-treat brain tumors
Disease control OngoingThis early-stage study tests whether combining vorasidenib (a targeted therapy) with pembrolizumab (an immunotherapy) is safe and can boost the immune system's attack on recurrent IDH-1 mutant gliomas, a type of brain tumor. About 60 adults with grade 2 or 3 tumors will receive t…
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Apr 29, 2026 02:07 UTC